Overview of Dr. Fidler
Dr. Mary Fidler is an oncologist in Chicago, IL and is affiliated with multiple hospitals in the area, including Rush University Medical Center and Rush Oak Park Hospital. She received her medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 16 years. Dr. Fidler accepts several types of health insurance, listed below. She is one of 58 doctors at Rush University Medical Center and one of 19 doctors at Rush Oak Park Hospital who specialize in Oncology. She has more than 60 publications and over 500 citings.
Office
1725 W Harrison St
Suite 1010
Chicago, IL 60612
Education & Training
Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2001 - 2004
Albert Einstein College of MedicineClass of 2001
Certifications & Licensure
IL State Medical License 2001 - 2026- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
- Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
- Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer Start of enrollment: 2019 Aug 02
Publications & Presentations
PubMed
- 4705 citationsPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Roy S. Herbst, Paul Baas, Dong Wan Kim, Enriqueta Felip, Jose Luis Perez-Gracia
Lancet. 2016-04-09 - 969 citationsPembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, p...Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra
Lancet. 2019-01-12 - 66 citationsPhase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma.David Cognetti, Jennifer Johnson, Joseph Curry, Samith T. Kochuparambil, Darren McDonald
Head & Neck. 2021-10-09
Press Mentions
Philip Bonomi, MD, Retiring from Clinical Service in JuneMay 30th, 2022- First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-Based BiomarkerMay 26th, 2021
- Biodesix, Addario Lung Cancer Institute Enroll First Patient in NSCLC Biomarker StudyMay 26th, 2021
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOFirst Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
